Your browser doesn't support javascript.
loading
Standard treatment with bevacizumab as targeted therapy in cervical cancer
Enríquez-Aceves, Isabel; Galicia-Carmona, Tatiana; Coronel-Martínez, Jaime A.; Espinosa-Romero, Raquel; Calderillo-Ruíz, Germán; Cortés-Esteban, Patricia; Cetina-Pérez, Lucely.
Affiliation
  • Enríquez-Aceves, Isabel; Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Department of Medical Oncology. León. MX
  • Galicia-Carmona, Tatiana; Instituto Nacional de Cancerología. Department of Clinical Research. Mexico City. MX
  • Coronel-Martínez, Jaime A.; Instituto Nacional de Cancerología. Department of Clinical Research. Mexico City. MX
  • Espinosa-Romero, Raquel; Instituto Nacional de Cancerología. Department of Medical Oncology. Mexico City. MX
  • Calderillo-Ruíz, Germán; Instituto Nacional de Cancerología. Department of Medical Oncology. Mexico City. MX
  • Cortés-Esteban, Patricia; Centro Médico Nacional 20 de Noviembre. Department of Medical Oncology. Mexico City. MX
  • Cetina-Pérez, Lucely; Instituto Nacional de Cancerología. Department of Clinical Research. Mexico City. MX
Rev. invest. clín ; 72(4): 213-218, Jul.-Aug. 2020.
Article in En | LILACS | ID: biblio-1251858
Responsible library: BR1.1
ABSTRACT
ABSTRACT Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient's quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Uterine Cervical Neoplasms / Bevacizumab Type of study: Prognostic_studies Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Rev. invest. clín Journal subject: MEDICINA Year: 2020 Document type: Article Affiliation country: Denmark / India / Mexico Country of publication: Mexico
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Uterine Cervical Neoplasms / Bevacizumab Type of study: Prognostic_studies Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Rev. invest. clín Journal subject: MEDICINA Year: 2020 Document type: Article Affiliation country: Denmark / India / Mexico Country of publication: Mexico